Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2007-03-08
2011-10-25
Andres, Janet (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C544S237000, C546S113000, C546S139000
Reexamination Certificate
active
08044242
ABSTRACT:
The present invention relates generally to novel 2-(aryloxy)acetamides of Formula (I):or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables W, Y, Z, R7, R8, and R9are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.
REFERENCES:
patent: 5023236 (1991-06-01), Edgington et al.
patent: 5583147 (1996-12-01), Ko et al.
patent: 5843442 (1998-12-01), Soule et al.
patent: 5866542 (1999-02-01), Vlasuk et al.
patent: 6140353 (2000-10-01), Ackermann et al.
patent: 6638980 (2003-10-01), Su et al.
patent: 6946489 (2005-09-01), Juraszyk et al.
patent: 7273867 (2007-09-01), Dorsch et al.
patent: 2002/0004608 (2002-01-01), Alig et al.
patent: 2003/0135055 (2003-07-01), Dorsch et al.
Arnold, C. Shane, et al., “The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor”, Thrombosis Research, vol. 117, pp. 343-349 (2006).
Carson, S.D. et al., “The role of tissue factor in the production of thrombin”, Blood Coagulation and Fibrinolysis, vol. 4, pp. 281-292 (1993).
Frédérick, R. et al., “Modulators of the Coagulation Cascade: Focus and Recent Advances in Inhibitors of Tissue Factor, Factor VIIa and their Complex”, Current Medicinal Chemistry, vol. 12, pp. 397-417 (2005.
Giesen, P. et al., “Blood-borne tissue factor: Another view of thrombosis”, PNAS, vol. 96, pp. 2311-2315 (1999).
Girard, T. et al., “The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation”, Current Opinion in Pharmacology, vol. 1, pp. 159-163 (2001).
Himber, J. et al., “Inhibition of tissue factor limits the growth of venous thrombus in the rabbit”, J. of Thrombosis and Haemostasis, vol. 1, pp. 889-895 (2003).
Hirsh, J. et al., “New anticoagulants”, Blood, vol. 105, pp. 453-463 (2005).
Hoffman, M., “A cell-based model of coagulation and the role of factor VIIa”, Blood reviews, vol. 17, pp. S1-S5 (2003).
Lazarus, R. et al., “Inhibitors of Tissue Factor Factor VIIa for Anticoagulant Therapy”, Current Medicinal Chemistry, vol. 11, pp. 2275-2290 (2004).
Lee, A. et al., “Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement”, Circulation, vol. 104, pp. 74-78 (2001).
Moons, A. et al., “Recombinant Nematode Anticoagulant Protein c2, an Inhibitor of the Tissue Factor/Factor VIIa Complex, in Patients Undergoing Elective Coronary Angioplasty”, J. of the American College of Cardiology, vol. 41(12), pp. 2147-2153 (2003).
Morrissey, J.H., “Tissue factor: in at the start . . . and the finish?”, J. of Thrombosis and Haemostasis, vol. 1, pp. 878-880 (2003).
Morrissey, J.H., “Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation”, Blood, vol. 81, pp. 734-744 (1993).
Olivero, A. et al., “A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo*”, The J. of Biological Chemistry, vol. 280(10), pp. 9160-9169 (2005).
Suleymanov, O. et al., “Pharmacological Interruption of Acute Thrombus Formation with Minimal Hemorrhagic Complications by a Small Molecule Tissue Factor/Factor VIIa Inhibitor: Comparison to Factor Xa and Thrombin Inhibition in a Nonhuman Primate Thrombosis Model”, The J. of Pharmacology and Experimental Therapeutics, vol. 306(3), pp. 1115-1121 (2003).
Szalony, J. et al., “Administration of a small molecule tissue factor/Factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time”, Thrombosis Research, vol. 112, pp. 167-174 (2003).
Szalony, J. et al., “Pharmacological Intervention at Disparate Sites in the Coagulation Cascade: Comparison of Anti-thrombotic Efficacy vs. Bleeding Propensity in a Rat Model of Acute Arterial Thrombosis”, J. of Thrombosis and Thrombolysis, vol. 14(2), pp. 113-121 (2002).
Young, W. et al., “Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model”, Bioorganic & Medicinal Chemistry Letters, vol. 16, pp. 2037-2041 (2006).
Zbinden, K. et al., “Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity”, Bioorganic & Medicinal Chemistry Letters, vol. 14, pp. 5357-5369 (2006).
Zbinden, K. et al., “Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 15(3), pp. 817-822 (2004).
Nirschl Alexandra A.
Zhang Xiaojun
Andres Janet
Bristol--Myers Squibb Company
Reese Heidi
Sun Jing G.
LandOfFree
2-(aryloxy) acetamide factor VIIa inhibitors useful as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-(aryloxy) acetamide factor VIIa inhibitors useful as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-(aryloxy) acetamide factor VIIa inhibitors useful as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299242